Keywords: Biogen Idec, BG-12, MS, Multiple sclerosis, USA, FDA, Abbott Labs, Reata Pharma, Bardoxolone, Kidney disease, Type 2 diabetes

FDA extends PDUFA date for Biogen Idec's MS drug BG-12; Abbott and Reata's bardoxolone stalled

Article | 19 October 2012

Print This

Shares of US biotech firm Biogen Idec (Nasdaq: BIIB) fell 3% to $149.50 in premarket trading yesterday, when the company said that ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in